Immutep Ltd has released a press release.
US patent granted for IMP321
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- French Research Tax Credit Payment Received
- PRR commences randomised phase IIb clinical trial
- Prima commences recruitment for 2nd cohort of melanoma trial
- Prima Enters New MTA with CYTLIMIC
- Prima announces new LAG-3 agonist antibody product candidate
Later from Immutep
- PRR completes recruitment for 2nd patient cohort
- $492k R&D Tax Incentive Refund Received
- Approval received to commence 3rd cohort of melanoma trial
- IMP321 demonstrates positive safety & efficacy qualities
- USD 5 Million Capital Raising
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep